An interdisciplinary conceptual study of Artificial Intelligence (AI) for helping benefit-risk assessment practices

被引:2
|
作者
Chassang, Gauthier [1 ,2 ,3 ,4 ]
Thomsen, Mogens [1 ,2 ,3 ,4 ]
Rumeau, Pierre [4 ,5 ]
Sedes, Florence [4 ,6 ]
Delfin, Alejandra [1 ,2 ,4 ]
机构
[1] INSERM, UMR1295, CERPOP, Team BIOETHICS, F-31000 Toulouse, France
[2] Univ Paul Sabatier Toulouse 3, CERPOP, UMR1295, F-31000 Toulouse, France
[3] GIS Genotoul, Eth & Biosci Platform Genotoul Societal, Toulouse, France
[4] Univ Fed Toulouse UFT, Working Grp Digital & Robot Eth, Unesco Chair Eth Sci & Soc, Toulouse, France
[5] Grp Interet Publ E Sante Occitanie, Toulouse, France
[6] IRIT CNRS, Toulouse, France
关键词
AI Ethics; AI qualification matrix; benefit-risk assessment; conceptual analysis; interdisciplinary study; CONSCIOUSNESS;
D O I
10.3233/AIC-201523
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
We propose a comprehensive analysis of existing concepts of AI coming from different disciplines: Psychology and engineering tackle the notion of intelligence, while ethics and law intend to regulate AI innovations. The aim is to identify shared notions or discrepancies to consider for qualifying AI systems. Relevant concepts are integrated into a matrix intended to help defining more precisely when and how computing tools (programs or devices) may be qualified as AI while highlighting critical features to serve a specific technical, ethical and legal assessment of challenges in AI development. Some adaptations of existing notions of AI characteristics are proposed. The matrix is a risk-based conceptual model designed to allow an empirical, flexible and scalable qualification of AI technologies in the perspective of benefit-risk assessment practices, technological monitoring and regulatory compliance: it offers a structured reflection tool for stakeholders in AI development that are engaged in responsible research and innovation.
引用
收藏
页码:121 / 146
页数:26
相关论文
共 50 条
  • [31] Benefit-risk assessment for binary diagnostic tests
    Bai, Tianyu
    Huang, Lan
    Li, Meijuan
    Tiwari, Ram
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 760 - 775
  • [32] Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis
    Schmidt, H
    Woodcock, BG
    Geisslinger, G
    DRUG SAFETY, 2004, 27 (03) : 185 - 196
  • [33] Benefit-Risk Assessment of Sirolimus in Renal Transplantation
    Dirk R.J. Kuypers
    Drug Safety, 2005, 28 : 153 - 181
  • [34] Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
    Helmut Schmidt
    Barry G. Woodcock
    Gerd Geisslinger
    Drug Safety, 2004, 27 : 185 - 196
  • [35] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [36] Benefit-risk assessment of sirolimus in renal transplantation
    Kuypers, DRJ
    DRUG SAFETY, 2005, 28 (02) : 153 - 181
  • [37] Benefit-risk assessment of antileukotrienes in the management of asthma
    García-Marcos, L
    Schuster, A
    Pérez-Yarza, EG
    DRUG SAFETY, 2003, 26 (07) : 483 - 518
  • [38] A benefit-risk assessment of basiliximab in renal transplantation
    Boggi, U
    Danesi, R
    Vistoli, F
    Del Chiaro, M
    Signori, S
    Marchetti, P
    Del Tacca, M
    Mosca, F
    DRUG SAFETY, 2004, 27 (02) : 91 - 106
  • [39] Benefit-risk assessment of zaleplon in the treatment of insomnia
    Barbera, J
    Shaprio, C
    DRUG SAFETY, 2005, 28 (04) : 301 - 318
  • [40] Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia
    Joseph Barbera
    Colin Shapiro
    Drug Safety, 2005, 28 : 301 - 318